Abstracts tagged "Biomarkers"

Abstract Number: 2578 • ACR Convergence 2024
Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
Yoshiya Tanaka¹, Atsushi Kumanogoh², Tatsuya Atsumi³, Tomonori Ishii⁴, Fumitoshi Tago⁵, Mari Aoki⁵, Shintaro Yamamuro⁵, Keisuke Sakayori⁵, Kentaro Takahashi⁵ and Shizuo Akira⁶, ¹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²Osaka University, Osaka, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, sendai, Japan, ⁵Eisai Company, Ltd., Tokyo, Japan, ⁶Osaka University Immunology Frontier Research Center, Osaka, Japan
Background/Purpose: There is strong evidence for the relationship between Toll-like receptor (TLR)7/8 and systemic lupus erythematosus (SLE) pathophysiology. Dual inhibition of TLR7/8 will modulate innate…
Abstract Number: 0271 • ACR Convergence 2024
Intercritical Gout Represents a Systemic Inflammatory State
Tanner Ourada¹, Austin Wheeler², Michael Duryee², Bryant England², Richard Reynolds³, James O'Dell², Jeff Newcomb², Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls², ¹University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: The presence of systemic inflammation during gout flares is well characterized. While initial research suggests inflammation persists in intercritical gout, these reports have come…
Abstract Number: 0470 • ACR Convergence 2024
New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², gonzalo Ocejo-Viñals³, Victor M. Mora-Cuesta⁴, David Iturbe-Fernández⁴, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁵, Mónica Renuncio-García⁶, Elena González López³, José M. Cifrián⁷, Ricardo Blanco-Alonso⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁶Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of death in rheumatoid arthritis (RA) patients [1]. Early diagnosis of RA-ILD+ is critical…
Abstract Number: 0610 • ACR Convergence 2024
Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)
Xiaoping hong and liancheng lin, The Second Clinical Medical College of Jinan University, Shenzhen, China (People's Republic)
Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine the relative…
Abstract Number: 0725 • ACR Convergence 2024
Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Lucy Eunju Lee¹, Taejun Yoon², Yong-Beom Park² and Sang-Won Lee², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glial fibrillary acidic protein (GFAP), an intermediate filament protein produced by astrocytes in the CNS, has been identified as a biomarker for disease activity…
Abstract Number: 0863 • ACR Convergence 2024
The Development of Future Radiographic Knee Osteoarthritis Can Be Predicted by Peripheral Blood Epigenetic Models
Cindy Miranda¹, Nicholas Hannebutt², Gabby dyson³, Montana Barrett⁴, Aleksander Szymczak³ and Matlock Jeffries³, ¹Oklahoma Medical Research Foundation, Yukon, OK, ²Oklahoma Medical Research Foundation, Spencer, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴University of Oklahoma, Cement, OK
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes. However, we do not yet have robust biomarkers…
Abstract Number: 1110 • ACR Convergence 2024
Microvascular Abnormalities in COVID-19 Survivors and LONG COVID
Rosanna Campitiello¹, Emanuele Gotelli², Elvis Hysa³, Carmen Pizzorni⁴, Alberto Sulli⁵, Sabrina Paolino⁶, Alessandro Pinelli⁷, Tamara Vojinovic², vanessa smith⁸ and Maurizio Cutolo², ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Liguria, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁵Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy, ⁶Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, ⁸Ghent University Hospital, Gent, Belgium
Background/Purpose: Coronavirus disease 2019 (COVID-19) is an infective disease known to cause mainly respiratory symptoms along with a wide range of systemic manifestations [1]. Long…
Abstract Number: 1357 • ACR Convergence 2024
Kidney Function in Rheumatoid Arthritis: Estimating Glomerular Filtration Rate Using Creatinine versus Cystatin C in a Secondary Analysis of the TARGET Trial
Sho Fukui¹, Lesley Inker², Leah Santacroce³, Jon Giles⁴, Katherine Liao³, Joan Bathon⁵ and Daniel Solomon⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²Tufts Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Columbia University, NEW YORK, NY, ⁶Brigham and Women's Hospital, Newton, MA
Background/Purpose: Glomerular filtration rate (GFR) is difficult to measure in patients with RA since creatinine-based estimated glomerular filtration rate (eGFRcr) may overestimate GFR due to…
Abstract Number: 1638 • ACR Convergence 2024
Calprotectin, a Mechanistically Informed Biomarker for Clinically Isolated Aortitis
Katarina Kmetova¹, Emily Chong², NaveenKumar Somanathapura K³, Kavya Sugur², Lyndsay Kluge², Srilakshmi Yalavarthi³, Julia Ford³, Ora Singer⁴ and Yu Zuo³, ¹Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann arbor, Ann arbor, MI, ³University of Michigan, Ann arbor, MI, ⁴University of Michigan, Huntington Woods, MI
Background/Purpose: Clinically isolated aortitis (CIA) is aortitis in patients without evidence of systemic disease, infection, or involvement of other vascular territories. CIA is discovered incidentally…
Abstract Number: 1839 • ACR Convergence 2024
PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways
Xuan Fang, Xiangpei Li and Xiaomei Li, The First Affiliated Hospital of University of Science and Technology of China., He Fei, China (People's Republic)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…
Abstract Number: 2232 • ACR Convergence 2024
Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Nicole Wilson⁵, Susan Manzi⁵, Veena Joy⁶ and Tyler O'Malley⁷, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶ThermoFisher, Philadelphia, PA, ⁷Exagen, Vista, CA
Background/Purpose: Novel autoantibodies (Ab) capable of identifying unique subgroups of seronegative rheumatoid arthritis (SN-RA) while providing specificity for RA comparable to ACPA reflects an opportunity…
Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Melissa Fazzari¹, Jane Salmon², Marta Guerra², Nathalie Costedoat-Chalumeau³, Veronique LE GUERN⁴, Gaëlle Guettrot-Imbert⁴, Marta Mosca⁵, Dina Zucchi⁶, Chiara Tani⁷, Rebecca Fischer-Betz⁸, Isabell Haase⁹, Anna Broder¹⁰, Navneet Kaur¹¹, Jill Buyon¹², Brooke Cohen¹², Diane Kamen¹³, Jessica English¹⁴, Anna Arar¹³ and Mimi Kim¹⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²Hospital for Special Surgery, New York, NY, ³Inserm DR Paris 5, Paris, France, ⁴Cochin hospital, Paris, France, ⁵University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Italy, ⁸Uniklinik Düsseldorf, Düsseldorf, Germany, ⁹Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, ¹⁰Hackensack Network, Hackensack, NJ, ¹¹Touro University Medical Group, Sacramento, CA, ¹²NYU Grossman School of Medicine, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴Medical University of South Carolina, Johns Island, SC, ¹⁵Albert Einstein College of Medicine, Larchmont, NY
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…
Abstract Number: 2594 • ACR Convergence 2024
A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Saul Kivimae¹, Sandip Mukherjee², Phi Quach³, Rhoneil Pena⁴, Olga Zemska³, Michal Olszewski⁵, Jicai Huang³, Michael Labson⁶, Donald Walker¹, Mekhala Maiti⁷, Chakrapani Tripathi⁸, Thomas Chang³, Suresh Adapala⁹, Damon Hamel³, Katherine Brendza³, Takahiro Miyazaki³ and Jonathan Zalevsky¹, ¹Nektar Therapeutics, San Francisco, CA, ²Nurix Therapeutics, San Francisco, ³Nektar Therapeutics, San Francisco, ⁴Sutro Biopharma, South San Francisco, ⁵Vaxcyte, San Francisco, ⁶Guardant Health, Palo Alto, ⁷Alumis, Inc, South San Francisco, ⁸Theragent Inc, Arcadia, CA, ⁹Inotiv, Rockville, MD
Background/Purpose: Current standard of care chronic inflammatory disease therapies are designed to suppress inflammation and are not optimized for inflammation resolution and restoration of tissue…
Abstract Number: 0316 • ACR Convergence 2024
Development and Evaluation of the Adult-onset Still’s Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment
Mayu Magi¹, Hiroto Yoshida¹, Hiroya Tamai², Kotaro Matsumoto², Keiko Yoshimoto², Yoshihiro Matsumoto¹, Tetsuhiro Soeda¹ and Yuko Kaneko², ¹Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ), an anti-IL-6 receptor antibody, has been shown to be effective in the treatment of adult-onset Still's disease (AOSD), a systemic inflammatory disease.…
Abstract Number: 0478 • ACR Convergence 2024
Skin Sodium in Patients with Rheumatoid Arthritis: Association with Blood Pressure and Disease Activity
Carolina Ramirez, Annette Oeser, Rachelle Crescenzi, C. Michael Stein and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Sodium is stored in tissues such as the skin where it may contribute to development and progression of autoimmune diseases and hypertension through activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].